Nonpegylated liposomal doxorubicin is highly active in patients with B and T/NK cell lymphomas with cardiac comorbidity or higher age

Annals of Hematology

Volumn 89, Issue 2, 2010, Pages 163-169

  Heintel, Daniel ^a   Skrabs, Cathrin ^a   Hauswirth, Alexander ^a   Eigenberger, Karin ^a   Einberger, Christine ^a   Raderer, Markus ^a   Sperr, Wolfgang R ^a   Knöbl, Paul ^a   Müllauer, Leonhard ^a   Uffmann, Martin ^a   Dieckmann, Karin ^a   Gaiger, Alexander ^a   Jäger, Ulrich ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cardiac comorbidity; Efficacy; Non hodgkin's lymphomas; Nonpegylated liposomal doxorubicin; Older age

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BORTEZOMIB; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; LIPOSOME; METHOTREXATE; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC ANTIBIOTIC;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; BLOOD TOXICITY; CANCER REGRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; COMORBIDITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXTRAVASATION; DRUG RESPONSE; GASTROINTESTINAL TOXICITY; HEART DISEASE; HUMAN; INFLAMMATION; LARGE CELL LYMPHOMA; LEUKOPENIA; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NK T CELL LYMPHOMA; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; T CELL LYMPHOMA; TISSUE INJURY; AGE; FEMALE; MALE; MIDDLE AGED; NONHODGKIN LYMPHOMA; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; FEMALE; HEART DISEASES; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, NON-HODGKIN; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 74049154849     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-009-0796-5     Document Type: Article

References (47)

1. Armitage JO, Potter JF (1984) Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: increased complications with advancing age. J Am Geriatr Soc 32:269-273.
2. Gomez H, Mas L, Casanova L et al (1998) Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte- macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity. J Clin Oncol 16:2352-2358.
3. Peters FP, Lalisang RI, Fickers MM et al (2001) Treatment of elderly patients with intermediate- and high-grade non-Hodgkin's lymphoma: a retrospective population-based study. Ann Hematol 80:155-159.
4. Salminen EK (1995) The outcome of > or =70-year-old non-Hodgkin's lymphoma patients. Int J Radiat Oncol Biol Phys 32:349-353.
5. Tirelli U, Zagonel V, Serraino D et al (1988) Non-Hodgkin's lymphomas in 137 patients aged 70 years or older: a retrospective European Organization for Research and Treatment of Cancer Lymphoma Group study. J Clin Oncol 6:1708-1713.
6. Grann VR, Hershman D, Jacobson JS et al (2006) Outcomes and diffusion of doxorubicin-based chemotherapy among elderly patients with aggressive non-Hodgkin lymphoma. Cancer 107:1530-1541.
7. Kouroukis CT, Browman GP, Esmail R et al (2002) Chemotherapy for older patients with newly diagnosed, advanced-stage, aggressive-histology non-Hodgkin lymphoma: a systematic review. Ann Intern Med 136:144-152.
8. Martelli M, Guglielmi C, Coluzzi S et al (1993) P-VABEC: a prospective study of a new weekly chemotherapy regimen for elderly aggressive non-Hodgkin's lymphoma. J Clin Oncol 11:2362-2369.
9. O'Reilly SE, Connors JM, Howdle S et al (1993) In search of an optimal regimen for elderly patients with advanced-stage diffuse large-cell lymphoma: results of a phase II study of P/DOCE chemotherapy. J Clin Oncol 11:2250-2257.
10. Sonneveld P, Michiels JJ (1990) Full dose chemotherapy in elderly patients with non-Hodgkin's lymphoma: a feasibility study using a mitoxantrone containing regimen. Br J Cancer 62:105-108.
11. Tirelli U, Zagonel V, Sorio R et al (1994) Mitoxantrone in combination with etoposide and prednimustine in patients older than 70 years with unfavorable non-Hodgkin's lymphoma: a prospective study in 52 patients. Semin Hematol 31:13-22.
12. Zinzani PL, Gherlinzoni F, Storti S et al (2002) Randomized trial of 8-week versus 12-week VNCOP-B plus G-CSF regimens as front-line treatment in elderly aggressive non-Hodgkin's lymphoma patients. Ann Oncol 13:1364-1369.
13. Zinzani PL, Storti S, Zaccaria A et al (1999) Elderly aggressivehistology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients. Blood 94:33-38.
14. Singal PK, Iliskovic N (1998) Doxorubicin-induced cardiomyopathy. N Engl J Med 339:900-905.
15. Von Hoff DD, Layard MW, Basa P et al (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710-717.
16. Hequet O, Le QH, Moullet I et al (2004) Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol 22:1864-1871.
17. Limat S, Demesmay K, Voillat L et al (2003) Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma. Ann Oncol 14:277-281.
18. Hershman DL, McBride RB, Eisenberger A et al (2008) Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. J Clin Oncol 26(19):3159-3165.
19. Batist G, Barton J, Chaikin P et al (2002) Myocet (liposomeencapsulated doxorubicin citrate): a new approach in breast cancer therapy. Expert Opin Pharmacother 3(12):1739-1751.
20. Chrischilles EA, Link BK, Scott SD et al (2003) Factors associated with early termination of CHOP therapy and the impact on survival among patients with chemosensitive intermediate-grade non-Hodgkin's lymphoma. Cancer Control 10:396-403.
21. Jensen BV, Skovsgaard T, Nielsen SL (2002) Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 13(5):699-709.
22. Hochster H, Liebes L, Wadler S et al (1992) Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. J Natl Cancer Inst 84 (22):1725-1730.
23. Swain SM, Whaley FS, Gerber MC et al (1997) Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicincontaining therapy. J Clin Oncol 15:1333-1340.
24. Magnus B, Tomas A, Anders A et al (2008) CNOP (mitoxantrone) chemotherapy is inferior to CHOP (doxorubicin) in the treatment of patients with aggressive non-Hodgkin lymphoma (metaanalysis). Eur J Haematol 80(6):477-482.
25. Nakamae H, Tsumura K, Terada Y et al (2005) Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer 104:2492-2498.
26. Zaja F, Tomadini V, Zaccaria A et al (2006) CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma 47:2174-2180.
27. Tsavaris N, Kosmas C, Vadiaka M et al (2002) Pegylated liposomal doxorubicin in the CHOP regimen for older patients with aggressive (stages III/IV) non-Hodgkin's lymphoma. Anticancer Res 22:1845-1848.
28. Visani G, Isidori A (2009) Nonpegylated liposomal doxorubicin in the treatment of B-cell non-Hodgkins lymphoma: where we stand. Expert Rev Anticancer Ther 9(3):357-363.
29. Rigacci L, Mappa S, Nassi L et al (2007) Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines. Hematol Oncol 25:198-203.
30. Visani G, Ferrara F, Alesiani F et al (2008) R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphom a: a pilot study. Leuk Lymphoma 49(6):1081-1086.
31. de Leval L, Gaulard P (2008) Pathobiology and molecular profiling of peripheral T-cell lymphomas. Hematology Am Soc Hematol Educ Program 2008:272-279.
32. Savage K (2008) Prognosis and primary therapy in peripheral Tcell lymphomas. Hematology Am Soc Hematol Educ Program 2008:280-288.
33. Schützinger C, Esterbauer H, Hron G et al (2008) Prognostic value of T-cell receptor γ rearrangement in peripheral blood or bone marrow of patients with peripheral T-cell lymphomas. Leuk Lymphoma 49(2):237-246.
34. Armitage J, Vose J, Weisenburger D et al (2008) International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: pathophysiology findings and clinical outcomes. J Clin Oncol 26 (25):4124-4130.
35. Horwitz S (2008) Novel therapies and role of transplant in the treatment of peripheral T-cell lymphomas. Hematology Am Soc Hematol Educ Program 2008:289-296.
36. Pro B, Fayad L, Romaguera J et al (2007) Preliminary results of a phase II study of HCVlDDoxil alternated with methotrexatecytarabine in patients with newly diagnosed T-cell lymphoma. Blood 110 (abstract #3456).
37. Swerdlow SH, Campo E, Harris NL et al (2008) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. International Agency for Research on Cancer, Lyon.
38. Cheson BD (2008) New response criteria for lymphomas in clinical trials. Ann Oncol 19(4):35-38.
39. Tulpule A, Espina BM, Berman N et al (2006) Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. Clin Lymphoma Myeloma 7(1):59-64.
40. Cortes J, DiCosimo S, Climent MA et al (2009) Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study. Clin Cancer Res 15(1):307-314.
41. Weber M, Hamm C (2006) Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart 92(6):843-849.
42. Doust JA, Glasziou PP, Pietrzak E et al (2004) Systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. Arch Intern Med 164:1978-1984.
43. Perik PJ, De Vries EG, Boomsma F et al (2005) Use of natriuretic peptides for detecting cardiac dysfunction in long-term diseasefree breast cancer survivors. Anticancer Res 25(5):3651-3657.
44. Daugaard G, Lassen U, Bie P et al (2005) Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction. Eur J Heart Fail 7(5):940-941.
45. Meinardi MT, Van Veldhuisen DJ, Gietema JA et al (2001) Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol 19:2746-2753.
46. Nousiainen T, Vanninen E, Jantunen E et al (2002) Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction. J Intern Med 251(3):228-234.
47. Rudolph R, Stein SR, Patillo RA (1976) Skin ulcers due to adriamycin. Cancer 38:1087-1094.